Buyer	NHS England — not a council we hold
Supplier	Abbvie Ltd
Supplier	Accord-UK Ltd
Supplier	Almirall
Supplier	Amgen Ltd
Supplier	AstraZeneca
Supplier	Aventis Pharma ltd t/a Sanofi
Supplier	Bayer plc
Supplier	Biogen
Supplier	Celltrion Healthcare United Kingdom Limited
Supplier	Chugai Pharma UK Ltd
Supplier	CST Pharma Limited
Supplier	Dr.Reddy's Laboratories (UK) Limited
Supplier	Eli Lilly & Company Ltd
Supplier	Galapagos Biotech Ltd
Supplier	Gedeon Richter UK Ltd
Supplier	GlaxoSmithKline UK Limited
Supplier	Ipsen
Supplier	Janssen-Cilag Ltd
Supplier	Kent Pharma Ltd
Supplier	Merck Serono Limited
Supplier	Merck Sharpe & Dohme (UK) Limited
Supplier	Merz
Supplier	Mylan
Supplier	Napp Pharmaceuticals Ltd
Supplier	Neon Healthcare Ltd
Supplier	Novartis Pharmaceuticals UK Ltd
Supplier	Novo Nordisk
Supplier	Organon Pharmaceuticals UK Ltd
Supplier	Orifarm UK
Supplier	Pfizer Ltd
Supplier	Pharmacosmos UK Ltd
Supplier	Roche Products Ltd
Supplier	Sandoz Ltd
Supplier	Sobi (Swedish Orphan Biovitrum Ltd)
Supplier	Sun Pharma UK Ltd
Supplier	Teva UK Limited
Supplier	Thornton and Ross Ltd
Supplier	Vifor Pharma UK Ltd
Supplier	Zentiva Pharma UK Ltd

Project Title: NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024 Offer reference number: CM/PHR/22/5678 CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

Runs	1 Mar 2024 to 31 Aug 2026
OCID	ocds-b5fd17-9914c3d5-bf44-4fbc-a2e3-258a048efd52
Notice	Read it on Contracts Finder

Figures are as published An award value in OCDS may be a framework ceiling rather than a sum anyone expects to spend, so a large figure here is not evidence of a large purchase.